V
Vinayak Muralidhar
Researcher at Brigham and Women's Hospital
Publications - 118
Citations - 1962
Vinayak Muralidhar is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 19, co-authored 110 publications receiving 1409 citations. Previous affiliations of Vinayak Muralidhar include Massachusetts Eye and Ear Infirmary & Harvard University.
Papers
More filters
Journal ArticleDOI
Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell Proliferation
Sophia Y. Lunt,Sophia Y. Lunt,Vinayak Muralidhar,Vinayak Muralidhar,Aaron M. Hosios,William J. Israelsen,Dan Y. Gui,Lauren Newhouse,Martin P. Ogrodzinski,Vivian C. Hecht,Kali Xu,Paula N. Marin Acevedo,Daniel P. Hollern,Gary Bellinger,Talya L. Dayton,Stefan Christen,Ilaria Elia,Anh T. Dinh,Gregory Stephanopoulos,Scott R. Manalis,Michael B. Yaffe,Eran R. Andrechek,Sarah-Maria Fendt,Matthew G. Vander Heiden,Matthew G. Vander Heiden +24 more
TL;DR: In this article, the authors examined how PKM2 deletion affects proliferation and metabolism in nontransformed, non-immortalized PKM-2-expressing primary cells and found that deletion in primary cells results in PKM1 expression and proliferation arrest.
Dysregulated metabolism contributes to oncogenesis
Matthew D. Hirschey,Ralph J. DeBerardinis,Anna Mae Diehl,Janice E. Drew,Christian Frezza,Michelle F. Green,Lee W. Jones,Young Hee Ko,Anne Le,Michael A. Lea,Jason W. Locasale,Valter D. Longo,Costas A. Lyssiotis,Eoin McDonnell,Mahya Mehrmohamadi,Gregory A. Michelotti,Michael P. Murphy,Peter L. Pedersen,Brad Poore,Lizzia Raffaghello,Jeffrey C. Rathmell,Sharanya Sivanand,Kathryn E. Wellen,Matthew G. Vander Heiden,Vinayak Muralidhar +24 more
TL;DR: Together, these results demonstrate that aberrant metabolism, once seen just as an epiphenomenon of oncogenic reprogramming, plays a key role in oncogenesis with the power to control both genetic and epigenetic events in cells.
Journal ArticleDOI
Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer
Kathryn T. Dinh,Gally Reznor,Vinayak Muralidhar,Brandon A. Mahal,Michelle D. Nezolosky,Toni K. Choueiri,Karen E. Hoffman,Jim C. Hu,Christopher Sweeney,Quoc-Dien Trinh,Paul L. Nguyen +10 more
TL;DR: Pharmacologic ADT increased the risk of depression and inpatient psychiatric treatment in this large study of elderly men with localized PCa, and this risk increased with longer duration of ADT.
Journal ArticleDOI
Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
Kathryn T. Dinh,Brandon A. Mahal,David R. Ziehr,Vinayak Muralidhar,Yu-Wei Chen,Vidya B. Viswanathan,Michelle D. Nezolosky,Clair J. Beard,Toni K. Choueiri,Neil E. Martin,Peter F. Orio,Christopher Sweeney,Quoc D. Trinh,Paul L. Nguyen +13 more
TL;DR: Nearly half of clinically low risk patients harbor Gleason 7 or greater, or pT3 or greater disease, and should be risk stratified by prostate specific antigen and percent positive cores for consideration of further testing before deciding on active surveillance.
Journal ArticleDOI
Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Santino Butler,Vinayak Muralidhar,Shuang G. Zhao,Nina N. Sanford,Idalid Franco,Zoe H. Fullerton,Janice Chavez,Anthony V. D'Amico,Felix Y. Feng,Timothy R. Rebbeck,Timothy R. Rebbeck,Paul L. Nguyen,Brandon A. Mahal +12 more
TL;DR: The extent to which US Preventive Services Task Force 2012 Grade D recommendations against prostate‐specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United States across stage, National Comprehensive Cancer Network risk groups, and age groups is investigated.